Start With EYLEA. Stay With EYLEA.

EYLEA offers flexible dosing options for certain approved indications in a single 2 mg (0.05 mL) formulation.1

Around 9.0 million doses since launch. Around 790,000 eyes treated with EYLEA since launch. Around 9.0 million doses since launch. Around 790,000 eyes treated with EYLEA since launch.

EYLEA First-Line Offers Flexibility Across Patient Types and Dosing Options Across Several Indications1

EYLEA 2 mg (0.05 mL) Dosing Schedule1

Eylea dosing for Wet AMD: Initial dosing 2 mg every 4 weeks x 3 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks. After one year of effective therapy 2 mg every 12 weeks. Eylea dosing for Wet AMD: Initial dosing 2 mg every 4 weeks x 3 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks. After one year of effective therapy 2 mg every 12 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 28 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every-4-week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every-8-week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.

Eylea dosing for Diabetic Macular Edema DME: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks. Eylea dosing for Diabetic Macular Edema DME: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every-4-week (monthly) dosing after the first 20 weeks (5 months).

Eylea dosing for Diabetic Retinopathy DR: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing 2 mg every 8 weeks or 2mg every 4 weeks. Eylea dosing for Diabetic Retinopathy DR: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing 2 mg every 8 weeks or 2mg every 4 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every-4-week (monthly) dosing after the first 20 weeks (5 months).

Eylea dosing for MEfRVO: 2 mg every 4 weeks. Eylea dosing for MEfRVO: 2 mg every 4 weeks.
Support for the reimbursement process
Reimbursement Support

Get help navigating the
reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details
Find out more about EYLEA's flexible dosing options for certaian approved indications in a 2mg formulation.
Dosing with EYLEA

EYLEA offers flexible dosing options
for certain approved indications in a single 2mg formulation.

Find out more
EYLEA news, events, and more
News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest
See More Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. May 2019.
  2. Data on file. Regeneron Pharmaceuticals, Inc.